Literature DB >> 11809698

Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects.

Annemieke de Jong1, Sjoerd H van der Burg, Kitty M C Kwappenberg, Jeanette M van der Hulst, Kees L M C Franken, Annemieke Geluk, Krista E van Meijgaarden, Jan Wouter Drijfhout, Gemma Kenter, Pieter Vermeij, Cornelis J M Melief, Rienk Offringa.   

Abstract

The incidence of genital human papillomavirus (HPV) infections is high in young, sexually active individuals. Most infections are cleared within 1 year after infection. The targets for the cellular immune response in this process of viral clearance remain to be identified, but the expression pattern of the E2 protein in early infection and low-grade cervical intraepithelial neoplasia renders this early protein a candidate antigen. Therefore, we studied the HPV16 E2-specific T-cell responses in more detail. Very strong proliferative responses against one or more peptide-epitopes derived from this antigen can be found in peripheral blood mononuclear cell cultures of approximately half of the healthy donors. Additional analysis revealed that at least a majority of these responses represent reactivity by memory CD4(+) T-helper (Th) 1-type cells capable of secreting IFN-gamma on antigenic stimulation. Interestingly, all of the E2 peptides against which strong responses were detected are clustered in the key functional domains of the E2 protein, which are conserved to considerable extent between HPV types. This suggests that HPV16 E2-specific Th memory may be installed through encounter with HPV types other than HPV16. Indeed, one HPV16 E2-specific Th clone was found to cross-react against homologuous peptides from other HPV types, but three other Th clones failed to show similar cross-reactivity. Therefore, part of the HPV16 E2-specific Th memory may relate to previous encounter of other HPV types, whereas the majority of the immune repertoire concerned is most likely established through infection with HPV16 itself. Our data are the first to reveal that the T-cell repertoire of healthy donors can contain particularly high frequencies of E2-specific memory Th cells and suggest that boosting of this immunity can be used for preventive and therapeutic vaccination against HPV-induced lesions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11809698

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  40 in total

1.  CD4+ cell count and HIV load as predictors of size of anal warts over time in HIV-infected women.

Authors:  Hung N Luu; E Susan Amirian; Wenyaw Chan; R Palmer Beasley; Linda B Piller; Michael E Scheurer
Journal:  J Infect Dis       Date:  2012-01-13       Impact factor: 5.226

2.  Pathogen-specific T cell depletion and reactivation of opportunistic pathogens in HIV infection.

Authors:  Christof Geldmacher; Richard A Koup
Journal:  Trends Immunol       Date:  2012-03-05       Impact factor: 16.687

Review 3.  [Prophylactic and therapeutic vaccines against human papilloma virus].

Authors:  A E Albers; T K Hoffmann; J P Klussmann; A M Kaufmann
Journal:  HNO       Date:  2010-08       Impact factor: 1.284

4.  Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses.

Authors:  Marij J P Welters; Gemma G Kenter; Peggy J de Vos van Steenwijk; Margriet J G Löwik; Dorien M A Berends-van der Meer; Farah Essahsah; Linda F M Stynenbosch; Annelies P G Vloon; Tamara H Ramwadhdoebe; Sytse J Piersma; Jeanette M van der Hulst; A Rob P M Valentijn; Lorraine M Fathers; Jan W Drijfhout; Kees L M C Franken; Jaap Oostendorp; Gert Jan Fleuren; Cornelis J M Melief; Sjoerd H van der Burg
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-14       Impact factor: 11.205

5.  Immunosuppressive tumor microenvironment in cervical cancer patients.

Authors:  Sytse J Piersma
Journal:  Cancer Microenviron       Date:  2011-05-31

6.  Papillomavirus-specific CD4+ T cells exhibit reduced STAT-5 signaling and altered cytokine profiles in patients with recurrent respiratory papillomatosis.

Authors:  Eddie A James; James A DeVoti; David W Rosenthal; Lynda J Hatam; Bettie M Steinberg; Allan L Abramson; William W Kwok; Vincent R Bonagura
Journal:  J Immunol       Date:  2011-04-29       Impact factor: 5.422

Review 7.  Human Immunodeficiency Virus and Human Papilloma Virus - why HPV-induced lesions do not spontaneously resolve and why therapeutic vaccination can be successful.

Authors:  Sjoerd H van der Burg; Joel M Palefsky
Journal:  J Transl Med       Date:  2009-12-18       Impact factor: 5.531

Review 8.  Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions.

Authors:  Shreya Kanodia; Diane M Da Silva; W Martin Kast
Journal:  Int J Cancer       Date:  2008-01-15       Impact factor: 7.396

9.  Human papillomavirus 16-specific T cell responses in classic HPV-related vulvar intra-epithelial neoplasia. Determination of strongly immunogenic regions from E6 and E7 proteins.

Authors:  I Bourgault Villada; M Moyal Barracco; S Berville; M L Bafounta; C Longvert; V Prémel; P Villefroy; E Jullian; T Clerici; B Paniel; B Maillère; J Choppin; J G Guillet
Journal:  Clin Exp Immunol       Date:  2009-07-30       Impact factor: 4.330

10.  Human papillomavirus type 16 E7 peptide-directed CD8+ T cells from patients with cervical cancer are cross-reactive with the coronavirus NS2 protein.

Authors:  Katja Nilges; Hanni Höhn; Henryk Pilch; Claudia Neukirch; Kirsten Freitag; P J Talbot; Markus J Maeurer
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.